Fuente: FierceBiotech Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy, an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary endpoint of a phase 2 trial.